Back to top
more

Marinus Pharmaceuticals (MRNS)

(Real Time Quote from BATS)

$1.35 USD

1.35
779,267

+0.02 (1.50%)

Updated May 20, 2024 01:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MRNS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

2 items in cart

View Cart/Checkout

Marinus Pharmaceuticals, Inc. [MRNS]

Reports for Purchase

Showing records 21 - 40 ( 56 total )

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 21

03/22/2022

Company Report

Pages: 5

Ganaxolone Approval A Key Milestone With Resources to See Through Development Program; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 22

03/21/2022

Daily Note

Pages: 3

Ztalmy Approval Heralds the Start of Good Things; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 23

03/04/2022

Daily Note

Pages: 3

Marinus and Ovid Settle Over Ganaxolone IP; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 24

02/23/2022

Daily Note

Pages: 3

Delays in IV Franchise Studies, But Value Proposition Remains Unchanged and No Impact on Oral Programs; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 25

02/04/2022

Company Report

Pages: 6

Metabolite Study Shows No Genotoxicity, But EU CDD Review Modesty Prolonged for Unrelated Reasons; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 26

01/27/2022

Industry Report

Pages: 9

Rx for Portfolios, Part 2: Companies With Significant Upcoming Regulatory Decisions

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 27

12/07/2021

Daily Note

Pages: 4

Five Key Takeaways from Marinus AES Investor Event; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 28

11/10/2021

Company Report

Pages: 5

Quiet 3Q Call After Plenty of Updates at R&D Day; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 29

11/09/2021

Company Report

Pages: 6

3Q21: Lead Program May be Ready for Filing BLA in 2022

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 30

10/06/2021

Daily Note

Pages: 7

Marinus R&D Day: Plenty of Updates and Even More to Look Forward to; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 31

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MRNS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 32

08/18/2021

Daily Note

Pages: 5

Ganaxolone Shows Sufficient Benefit in TSC Phase 2, to Spur Phase 3 Initiation Planned for 4Q; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 33

08/11/2021

Company Report

Pages: 5

Progress Across Multiple Fronts for Ganaxolone Franchise; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 34

08/04/2021

Daily Note

Pages: 4

Marinus Files on CDD and Secures European Partner for Ganaxolone; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 35

05/21/2021

Company Report

Pages: 5

Ganaxolone Makes Further Progress with New Opportunities Emerging; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 36

03/10/2021

Company Report

Pages: 5

More Data in PCHD-19 RE and TSC Build Case for Ganaxolone in Orphan Epilepsies; Reiterate Buy, PT to $38

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 37

01/29/2021

Industry Report

Pages: 7

Takeaways From Our Coverage at the 2021 H.C. Wainwright BioConnect Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 38

01/27/2021

Industry Report

Pages: 15

2021 Roadmap of Key Events Across Our Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 50.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 39

01/14/2021

Company Report

Pages: 4

FDA Suggests One Pivotal Trial is Sufficient for CDD NDA, Filing Expected in 2Q

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 40

09/28/2020

Company Report

Pages: 4

Update Price Target After Reverse Stock Split; Reiterate Buy, Adjust Price Target to $35

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party